This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Centene (CNC) Down 2.9% Since Last Earnings Report?
by Zacks Equity Research
Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acadia Healthcare Q4 Earnings Miss on Reduced Length of Stay
by Zacks Equity Research
ACHC expects revenues to be between $3.3 billion and $3.4 billion in 2025.
Teladoc Health Q4 Loss Widens on Soft Integrated Care Unit
by Zacks Equity Research
TDOC expects revenues in the Integrated Care segment to witness 0-3% growth on a year-over-year basis.
Universal Health Q4 Earnings Beat on Strong Adjusted Admissions
by Zacks Equity Research
UHS' fourth-quarter earnings benefit from rising admissions and patient days. Higher expenses partially offset the positives.
Acadia Healthcare to Report Q4 Earnings: Can it Overcome Rising Costs?
by Zacks Equity Research
ACHC's fourth-quarter earnings are likely to have benefited from growing patient days and admissions.
Universal Health to Report Q4 Earnings: What Do the Estimates Say?
by Zacks Equity Research
UHS' fourth-quarter earnings are likely to have benefited from growing admissions and patient days.
Select Medical Q4 Earnings Miss Estimates, Stock Down 7.2%
by Zacks Equity Research
SEM expects revenues to be between $5.4 billion and $5.6 billion, the mid-point of which implies 5.8% growth from the 2024 figure of $5.2 billion.
Markets Await Consumer Sentiment Data
by Zacks Equity Research
Markets Await Consumer Sentiment Data
Pre-Market Dow Sinks on UNH Report; Econ Reports After the Open
by Mark Vickery
The DOJ is bringing a civil case against UnitedHealthcare (UNH) -- the largest healthcare company in the world.
Community Health Q4 Earnings Miss on Lower Adjusted Admissions
by Zacks Equity Research
CYH expects 2025 capital expenditures to be in the range of $350-$4000 million.
Pediatrix Medical Gears Up for Q4 Results: What to Expect?
by Zacks Equity Research
MD's fourth-quarter results are likely to reflect declining revenues and expenses.
Can Community Health Beat Q4 Earnings on Growing Occupancy?
by Zacks Equity Research
CYH's fourth-quarter earnings are likely to have been aided by higher revenue per adjusted admission.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Can Tenet Healthcare Navigate Through Lower Revenues in Q4?
by Zacks Equity Research
THC's fourth-quarter results are likely to reflect growing patient admissions, utilization and patient days.
Company News for Jan 31, 2025
by Zacks Equity Research
Companies in The News Are: MA,NOC,CI,SIRI
Cigna Q4 Earnings Miss Estimates on Decline in Medical Membership
by Zacks Equity Research
CI's Q4 results reflect a decline in Individual and Family Plans customers. Management expects 2025 adjusted EPS at a minimum of $29.50, which indicates growth of at least 7.9% from the 2024 figure.
Cigna (CI) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cigna (CI) Lags Q4 Earnings Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of -15.20% and 3.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Bet on These 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Tyson Foods, Cigna Group, Eldorado Gold, ChampionX and Akamai Technologies.
Rising Medical Costs to Affect Cigna Q4 Earnings? Check Estimates Here
by Zacks Equity Research
CI's fourth-quarter results are likely to have benefited from growing premiums and pharmacy revenues.
Humana (HUM) Soars 3.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Humana (HUM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Elevance Health Q4 Countdown: Smart Move to Buy or Stick With Hold?
by Zacks Equity Research
ELV's fourth-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FTC Report Reveals PBM Practices Impacting Competition and Drug Costs
by Zacks Equity Research
The report comes at a time when insurers are grappling with rising medical costs.
Cigna Stock Plunges 18.7% in 3 Months: Should You Buy, Hold or Sell?
by Zacks Equity Research
Despite market challenges, CI's strong fundamentals and growth drivers make it worth holding for long-term investors looking to capitalize on future recovery opportunities.